Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Glioblastoma in Elderly Patients: Current Management and Future Perspectives.
Cancers (Basel)
March 2019
IRCCS Neuromed, 86077 Pozzilli (IS), Italy.
The incidence of glioblastoma (GBM) in the elderly population is slowly increasing in Western countries. Current management includes surgery, radiation therapy (RT) and chemotherapy; however, survival is significantly worse than that observed in younger patients and the optimal treatment in terms of efficacy and safety remains a matter of debate. Surgical resection is often employed as initial treatment for elderly patients with GBM, although the survival benefit is modest.
View Article and Find Full Text PDFA Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
Clin Lung Cancer
January 2017
Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address:
Background: Adjuvant chemotherapy (ACT) improved survival in the NCIC Clinical Trials Group JBR.10 trial of resected stage IB/II non-small-cell lung cancer. A prognostic 15-gene expression signature was developed, which may also predict for benefit from ACT.
View Article and Find Full Text PDFGemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.
J Natl Cancer Inst
July 2015
Affiliations of authors: Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada (MCC, KRI, SH, NM); NCIC Clinical Trials Group, Kingston, Ontario, Canada (AEH, YS, NR, LS, AL, BEC, NM); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (MC, VK); Juravinski Hospital and Cancer Centre and McMaster University, Hamilton, Ontario, Canada (JS, CTK, RMM); Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada (SC, DM); Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada (TB); Cancercare Manitoba, Winnipeg, Manitoba, Canada (DS); Hopital Charles Lemoyne, Montreal, Quebec, Canada (PD).
Background: The NCIC CTG LY.12 study showed that gemcitabine, dexamethasone, and cisplatin (GDP) were noninferior to dexamethasone, cytarabine, and cisplatin (DHAP) in patients with relapsed or refractory aggressive histology lymphoma prior to autologous stem cell transplantation. We conducted an economic evaluation from the perspective of the Canadian public healthcare system based on trial data.
View Article and Find Full Text PDFIntegrating health-related quality of life findings from randomized clinical trials into practice: an international study of oncologists' perspectives.
Qual Life Res
June 2015
Division of Cancer Care and Epidemiology, Level 2, Queen's Cancer Research Institute, 10 Stuart St., Kingston, ON, K7L 3N6, Canada,
Purpose: Although health-related quality of life (HRQL) is increasingly assessed in randomized controlled trials (RCTs), HRQL findings are not always incorporated into clinical decision making. We examined the current perspectives of oncologists on the use of HRQL findings from RCTs, and variation of these perspectives between countries and specialties.
Methods: A cross-sectional e-survey of oncologist members of the NCIC Clinical Trials Group, the United Kingdom National Cancer Research Institute Clinical Studies Groups, and the Australia/New Zealand cancer clinical trials network was conducted.
Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
Lung Cancer
October 2013
NCIC Clinical Trials Group, 10 Stuart Street, Kingston, Ontario, K7L 3N6, Canada. Electronic address:
Background/objective: Non-platinum-based chemotherapy is a potential alternative to platinum doublet therapy for advanced non-small cell lung cancer in selected patients. We determined the cost-effectiveness of gemcitabine/vinorelbine (GEMVIN), versus cisplatin/gemcitabine (PG) or cisplatin/vinorelbine (PV), from a government payer perspective.
Methods: Results from a randomized trial of GEMVIN versus PG or PV demonstrated no significant difference in global quality of life (primary endpoint) or overall survival between regimens, but superior progression-free survival for platinum-based regimens.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!